Dr Mary Carroll
MB BSM MRCP, MD, FRCP
Respiratory Consultant
Profile page(s)
Dr Carroll has helped developed the technique of nasal ventilation and has applied it for use in Cystic Fibrosis. She was involved in the discovery that nebulised heparin thins sputum so making it easier to expel. Currently she is involved in a large number of commercial and academic research projects, testing and advising new treatments for people with CF. She has a particular interest and is an international expert in studies using new molecular techniques to better identify the bacteria that cause lung infections. She has a large research portfolio consisting of phase 1 to phase III trials, looking at CFTR modulators and novel treatments. She is an active member of the European Cystic Fibrosis Society Clinical Trials Network (ECFS-CTN), European Lung Network (ERN), and CF Trust Clinical Trials Accelerator Platform Centre.
Landmark publications:
Bevan A, Hoo ZH, Totton N, et al. Corrigendum to "Using a learning health system to understand the mismatch between medicines supply and actual medicines use among adults with cystic fibrosis" [J Cyst Fibros (2022), 21/2, 323-331]. J Cyst Fibros. 2022;21(5):893-897. doi:10.1016/j.jcf.2022.07.011
Shoemark A, Griffin H, Wheway G, et al. Genome sequencing reveals underdiagnosis of primary ciliary dyskinesia in bronchiectasis. Eur Respir J. 2022;60(5):2200176. Published 2022 Nov 17. doi:10.1183/13993003.00176-2022
van Haren FMP, Richardson A, Yoon HJ, et al. INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID-19 (INHALE-HEP): Protocol and statistical analysis plan for an investigator-initiated international metatrial of randomised studies. Br J Clin Pharmacol. 2021;87(8):3075-3091. doi:10.1111/bcp.14714
Wheway G, Thomas NS, Carroll M, et al. Whole genome sequencing in the diagnosis of primary ciliary dyskinesia. BMC Med Genomics. 2021;14(1):234. Published 2021 Sep 23. doi:10.1186/s12920-021-01084-w
Cuthbertson L, Walker AW, Oliver AE, et al. Lung function and microbiota diversity in cystic fibrosis. Microbiome. 2020;8(1):45. Published 2020 Apr 2. doi:10.1186/s40168-020-00810-3
Rogers GB, Shaw D, Marsh RL, Carroll MP, Serisier DJ, Bruce KD. Respiratory microbiota: addressing clinical questions, informing clinical practice. Thorax. 2015;70(1):74-81. doi:10.1136/thoraxjnl-2014-205826
Major grants:
Co-applicant BRC
North American Cystic Fibrosis Foundation
CF Trust, Clinical Trials Accelerator Platform Centre- Early Phase Grant
NIHR RFPB - Exercise as Airway Clearance Technique
BRONCH UK – MRC Funded – Bronchiectasis Biobank
Impact example:
Recent publications in PCD illustrates whole genome sequencing is revealing a greater number of patients in Bronchiectasis clinics that have PCD than previously thought, thus speaking to an unmet need.